Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced topline results from the Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Leerink Partners Reiterates Outperform on Regeneron (REGN) October 3, 2016 8:48 AM Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMDSeptember 30, 2016 10:16 AM Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo DataSeptember 30, 2016 8:05 AM Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular DegenerationSeptember 30, 2016 7:00 AM